A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 55-62

  Goicoechea, Miguel ^a   Vidal, Andrea ^a   Capparelli, Edmund ^a   Rigby, Andrew ^a   Kemper, Carol ^b   Diamond, Catherine ^c   Witt, Mallory D ^d   Haubrich, Richard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; LOPINAVIR; VIRUS RNA;

ADULT; ARTICLE; ARTIFICIAL INTELLIGENCE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPUTER AIDED DESIGN; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG RESEARCH; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TECHNIQUE;

ADULT; ALGORITHMS; ANTI-RETROVIRAL AGENTS; ARTIFICIAL INTELLIGENCE; BAYES THEOREM; BENZOXAZINES; CALIFORNIA; COMPUTER SYSTEMS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EXPERT SYSTEMS; FEMALE; FUZZY LOGIC; HIV INFECTIONS; HUMANS; MALE; MODELS, BIOLOGICAL; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; PYRIMIDINONES; REPRODUCIBILITY OF RESULTS;

EID: 33847354202     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS 2003; 17:1157-1165.
2. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS 2000; 14:1333-1339.
3. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration- controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002; 16:551-560.
4. Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 1999; 13:1873-1880.
5. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
7. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23:394-398.
8. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral regimens containing efavirenz and/or nelfinavir: an adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192:1931-1942.
9. Burger DM, Grintjes KJ, Lotgering FK, Koopmans PP. Therapeutic drug monitoring of nelfinavir in pregnancy: a case report. Ther Drug Monit 2004; 26:576-578.
10. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76:588-597.
11. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J 2001; 20:746-751.
12. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28:1109-1118.
13. Boffito M, Acosta E, Burger D, et al. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther 2005; 10:375-392.
14. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit 2003; 25:73-80.
15. Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet 2004; 43:845-853.
16. Rousseau A, Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam Clin Pharmacol 2002; 16:253-262.
17. Best BWM, Goicoechea M, Kemper C, et al. Improved antiretroviral exposure with therapeutic drug monitoring. 13th Conference on Retrovimses & Opportunistic Infections. Denver, CO, USA, 5-8 February 2006. Abstract 589.
18. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004; 48:824-831.
19. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001; 15:F1-9.
20. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 1999; 48:712-715.
21. Feigenbaum EFP, Shrobe H. JTEC panel on knowledge-based systems in Japan. National Technical Information Service. Fuzzy Logic Research and LIFE; 1993 [cited 2006 June 21]. Available from: http://www.wtec.org/loyola/kb/toc.htm
22. De Luca A, Vendittelli M, Baldini F, et al. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. Antivir Ther 2004; 9:583-593.
23. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CE, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002; 7:123-129.
24. The HIV and protease sequence database at Stanford University. Available at: http://hivdb.standford.edu
25. Agence Nationale de Recherches sur le SIDA, groupe AC11. Available at: http://www.frenchresistance.org
26. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
27. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses 2002; 18:825-834.
28. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189-1196.
29. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
30. Marcelin AG, Cohen-Codar I, King MS, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49:1720-1726.
31. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med 2004; 5:352-359.
32. Clevenbergh P, Garraffo R, Durant J, Dellamonica P. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16:2311-2315.
33. Stahle L, Moberg L, Svensson JO, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26:267-270.
34. Winslow DE, Garber S, Reid C, et al. Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266. AIDS 1996; 10:1205-1209.